CANADA’S DRUG AGENCY ISSUES RECOMMENDATION TO REIMBURSE YORVIPATH® (PALOPEGTERIPARATIDE INJECTION) WITH CONDITIONS FOR ELIGIBLE ADULTS WITH CHRONIC HYPOPARATHYROIDISM

Reuters · 2d ago

Please log in to view news